Crossmark

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2021-003431

Published Online: 2021-11-08

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Yu, Hui

Chen, Ping

Xia, Liangping

Fu, Sha

Chen, Chen

Zhang, Xuanye

He, Lina

Zhang, Bei

Zhou, Yixin

Hong, Shaodong https://orcid.org/0000-0002-5632-6857
Funding

Funding for this research was provided by:

Natural Science Foundation of Guangdong Province (2019A1515011596, 2019A1515011090)

National Natural Science Funds of China (81903176, 81972898, 8217102281)

Medical Scientific Research Foundation of Guangdong Province (C2019110)
License Information

License valid from 2021-11-07